Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Deferred Revenue (2016 - 2018)

Corvus Pharmaceuticals' Current Deferred Revenue history spans 4 years, with the latest figure at $160000.0 for Q4 2018.

  • Quarterly Current Deferred Revenue fell 60.98% to $160000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $160000.0 through Dec 2018, down 60.98% year-over-year, with the annual reading at $160000.0 for FY2018, 60.98% down from the prior year.
  • Current Deferred Revenue came in at $160000.0 for Q4 2018, down from $435000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $435000.0 in Q3 2018 to a low of $160000.0 in Q4 2018.
  • The 4-year median for Current Deferred Revenue is $386000.0 (2017), against an average of $350000.0.
  • Year-over-year, Current Deferred Revenue soared 69.51% in 2016 and then crashed 60.98% in 2018.
  • Corvus Pharmaceuticals' Current Deferred Revenue stood at $223000.0 in 2015, then skyrocketed by 69.51% to $378000.0 in 2016, then grew by 8.47% to $410000.0 in 2017, then plummeted by 60.98% to $160000.0 in 2018.
  • Per Business Quant, the three most recent readings for CRVS's Current Deferred Revenue are $160000.0 (Q4 2018), $435000.0 (Q3 2018), and $427000.0 (Q2 2018).